Yang, MD
Bao Yang, Sliver Spring, MD US
Patent application number | Description | Published |
---|---|---|
20120112121 | EMULSIONS OF HEAT TRANSFER FLUIDS INCLUDING NANODROPLETS TO ENHANCE THERMAL CONDUCTIVITIES OF THE FLUIDS - A heat transfer fluid emulsion includes a heat transfer fluid, and liquid droplets dispersed within the heat transfer fluid, where the liquid droplets are substantially immiscible with respect to the heat transfer fluid and have dimensions that are no greater than about 100 nanometers. In addition, the thermal conductivity of the heat transfer fluid emulsion is greater than the thermal conductivity of the heat transfer fluid. | 05-10-2012 |
Bou-Kau Yang, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20080307297 | Method and System for Click-Thru Capability in Electronic Media - Methods and systems for capturing, collecting, analyzing and auditing of electronic documents. In an embodiment, there is provided the ability to present an audit function or “click thru” capability with respect to image files, non-structured text, non-structured html, and pdf documents. | 12-11-2008 |
Chaowei Yang, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090043486 | Near Real-time Traffic Routing - A near real-time physical transportation network routing system comprising: a traffic simulation computing grid and a dynamic traffic routing service computing grid. The traffic simulator produces traffic network travel time predictions for a physical transportation network using a traffic simulation model and common input data. The physical transportation network is divided into a multiple sections. Each section has a primary zone and a buffer zone. The traffic simulation computing grid includes multiple of traffic simulation computing nodes. The common input data includes static network characteristics, an origin-destination data table, dynamic traffic information data and historical traffic data. The dynamic traffic routing service computing grid includes multiple dynamic traffic routing computing nodes and generates traffic route(s) using the traffic network travel time predictions. | 02-12-2009 |
20100077403 | Middleware for Fine-Grained Near Real-Time Applications - A centralized scheduling server for scheduling fine-grained near real-time applications includes network ports, a central managing application, functional library(ies) and service processes. One port communicates with processing nodes over a private computer network. Processing nodes include processing node report processor node status to the server and execute scheduled tasks. The other port communicates with user devices through a public network. The central managing application manages fine-grained near real-time application. The functional library provides middleware core functionality. The service processes include: a resource manager, a submitter to place tasks on a task queue; and a dispatcher to dispatch tasks to processing nodes. A work flow process runs an optimized scheduling algorithm. | 03-25-2010 |
Chun-Chieh Yang, Greenbelt, MD US
Patent application number | Description | Published |
---|---|---|
20090087033 | Method and system for wholesomeness inspection of freshly slaughtered chickens on a processing line - An imaging system containing an electron-multiplying charge-coupled device detector and line-scan spectrograph is used for identifying wholesome and unwholesome freshly slaughtered chicken carcasses on high-speed commercial chicken processing lines. Multispectral imaging algorithms allow for real-time online identification of wholesome and unwholesome chicken carcasses. | 04-02-2009 |
20120008835 | Method and System for Wholesomeness Inspection of Freshly Slaughtered Chickens on a Processing Line - An imaging system containing an electron-multiplying charge-coupled device detector and line-scan spectrograph is used for identifying wholesome and unwholesome freshly slaughtered chicken carcasses on high-speed commercial chicken processing lines. Multispectral imaging algorithms allow for real-time online identification of wholesome and unwholesome chicken carcasses. | 01-12-2012 |
Chunzhang Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20140235649 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION - A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2A inhibitor or a histone deacetylase inhibitor. | 08-21-2014 |
Dajun Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20090010878 | Pulsatile dosing of gossypol for treatment of disease - This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 01-08-2009 |
20090082424 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 03-26-2009 |
20090092684 | SMALL MOLECULE ANTAGONISTS OF BCL-2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 04-09-2009 |
20090118377 | APOGOSSYPOLONE AND THE USES THEREOF - The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death. | 05-07-2009 |
20090175869 | Pulsatile Dosing of Gossypol for Treatment of Disease - This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 07-09-2009 |
20100069344 | SMALL MOLECULE ANTAGONISTS OF BCL2 FAMILY PROTEINS - The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of Bcl-2 family proteins. In particular, the present invention provides gossypol compounds (e.g., isomers, enantiomers, racemic compounds, metabolites, derivatives, pharmaceutically acceptable salts, in combination with acids or bases, and the like) and methods of using these compounds as antagonists of the anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2, Bcl-X | 03-18-2010 |
20100189683 | Pulsatile Dosing of Gossypol for Treatment of Disease - This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 07-29-2010 |
De Yang, Frederick, MD US
Patent application number | Description | Published |
---|---|---|
20100021488 | HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS - A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions. | 01-28-2010 |
20120269839 | HMGN POLYPEPTIDES AS IMMUNE ENHANCERS AND HMGN ANTAGONISTS AS IMMUNE SUPPRESSANTS - A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions. | 10-25-2012 |
Dongliang Yang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20150144765 | SYSTEM AND METHOD FOR IMPROVED FIXATION OF FLATS SEQUENCING SYSTEM LINEAR ACTUATOR - A system of mitigating force in a mechanical system, the system comprising a frame member, a first rail connected to the frame member, a second rail connected to the frame member and extending along the frame member in parallel to the first rail, an assembly movably engaging the first and second rails, and a first bracket located between the first and second rails, with at least one first bracket attachment secured to the frame member, the first bracket sharing an upper edge with a lower edge of the first rail, such that a downward force applied on the first rail is distributed to the first bracket and the frame member via the at least one first bracket attachment. | 05-28-2015 |
Fei Yang, Odenton, MD US
Patent application number | Description | Published |
---|---|---|
20100075626 | Geo-redundant and high reliability commercial mobile alert system (CMAS) - A Commercial Mobile Alert System (CMAS) providing redundant cell broadcast centers (CBC). Multiple CBCs are interfaced to any given base station controller (BSC) or radio network controller (RNC) to provide geo-redundancy and high availability so that the failure of one CBC or a cluster of CBCs at one site will not cause service interruption for the area controlled by the associated BSC or RNC or for the entire service area in the public land mobile network (PLMN) network. The BSC or RNC interfaces to multiple CBCs at multiple sites without changes to the otherwise conventionally existing BSC/RNC, 3GPP 23.041 standard architecture. | 03-25-2010 |
20140189112 | User Plane Location Services Over Session Initiation Protocol (SIP) - A method and mechanism to allow a location server to initiate a user plane location service (e.g., SUPL defined by OMA) procedure to a user plane enabled device via Instant Messaging, or alternatively, via an existing SIP session if a multimedia session is already established. The location request is signaled to the user plane enabled device via a SIP INFO message. The location request uses SIP messaging to overcome firewall and other network security issues. Location using SUPL over SIP may be provided about a caller making an E911 emergency call. An Instant Message may be sent to the user plane enabled device, e.g., a VoIP wireless phone. | 07-03-2014 |
20150111522 | Geo-Redundant and High Reliability Commercial Mobile Alert System (CMAS) - A Commercial Mobile Alert System (CMAS) providing redundant cell broadcast centers (CBC). Multiple CBCs are interfaced to any given base station controller (BSC) or radio network controller (RNC) to provide geo-redundancy and high availability so that the failure of one CBC or a cluster of CBCs at one site will not cause service interruption for the area controlled by the associated BSC or RNC or for the entire service area in the public land mobile network (PLMN) network. The BSC or RNC interfaces to multiple CBCs at multiple sites without changes to the otherwise conventionally existing BSC/RNC, 3GPP 23.041 standard architecture. | 04-23-2015 |
20150289092 | USER PLANE LOCATION SERVICES OVER SESSION INITIATION PROTOCOL (SIP) - A method and mechanism to allow a location server to initiate a user plane location service (e.g., SUPL defined by OMA) procedure to a user plane enabled device via Instant Messaging, or alternatively, via an existing SIP session if a multimedia session is already established. The location request is signaled to the user plane enabled device via a SIP INFO message. The location request uses SIP messaging to overcome firewall and other network security issues. Location using SUPL over SIP may be provided about a caller making an E911 emergency call. An Instant Message may be sent to the user plane enabled device, e.g., a VoIP wireless phone. | 10-08-2015 |
Gengcheng Yang, Germantown, MD US
Patent application number | Description | Published |
---|---|---|
20150050410 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE - The present invention provides edible compositions comprising a sweet taste modulator of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste in a food product. | 02-19-2015 |
Guangning Yang, Clarksville, MD US
Patent application number | Description | Published |
---|---|---|
20100080553 | AUTOMATIC LASER SHUTDOWN AND RECOVERY IN RESPONSE TO A LINK BREAK - A communication system may include a first control circuit to detect a break on a first optical link; a first optical source to supply a first optical signal on a second optical link in response to detecting the break on the first optical link, the first optical signal propagating in a first direction on the second optical link; a second control circuit to detect a presence of the first optical signal on the second optical link, and output a control signal in response to detecting the presence of the first optical signal; and a second optical source to supply a second optical signal on the second optical link, the second optical signal propagating in a second direction opposite the first direction, where the Raman pump is disabled in response to the control signal. | 04-01-2010 |
20130308663 | APPARATUS AND METHOD TO ENABLE PRECISION AND FAST LASER FREQUENCY TUNING - An apparatus and method is provided to enable precision and fast laser frequency tuning. For instance, a fast tunable slave laser may be dynamically offset-locked to a reference laser line using an optical phase-locked loop. The slave laser is heterodyned against a reference laser line to generate a beatnote that is subsequently frequency divided. The phase difference between the divided beatnote and a reference signal may be detected to generate an error signal proportional to the phase difference. The error signal is converted into appropriate feedback signals to phase lock the divided beatnote to the reference signal. The slave laser frequency target may be rapidly changed based on a combination of a dynamically changing frequency of the reference signal, the frequency dividing factor, and an effective polarity of the error signal. Feed-forward signals may be generated to accelerate the slave laser frequency switching through laser tuning ports. | 11-21-2013 |
Harry Hongjun Yang, Derwood, MD US
Patent application number | Description | Published |
---|---|---|
20130115295 | Rare Earth-Doped Up-Conversion Nanoparticles for Therapeutic and Diagnostic Applications - This invention provides a composition matter comprising rare earth-doped up-conversion nanoparticles (UCNPs) encapsulated with a silica shell. In one embodiment, a photosensitizer is incorporated into the silica shell. In another embodiment, the composition further comprises a targeting molecule. In still another embodiment, a small interfering RNA (siRNA) molecule is also attached to the silica shell with the targeting molecule. The invention further provides methods for synthesizing such compositions and for using them in therapeutic and diagnostic applications. These applications use infrared or near infrared activation to excite the UCNPs. | 05-09-2013 |
Hongjun Yang, Derwood, MD US
Patent application number | Description | Published |
---|---|---|
20130087467 | HIGH-PERFORMANCE ANALYTICAL INSTRUMENT AND METHOD - Apparatus and methods are provided for improving sensitivity, throughput, and efficiency of multi-analyte analytical testing. Specifically, an improved Electrochemiluminescence (ECL) analytical apparatus is provided for analytical chemistry, diagnostics, and environmental applications. The ECL apparatus comprises a 96 or more-well plate, where a microarray of working electrodes is placed in each well for high throughput and multi-analyte testing. The microarray of working electrodes connects with a counter electrode forming a two-electrode electrochemical system. Each well is electrically addressable, thereby controlling ECL reactions in flexible modes. The ECL apparatus further comprises a detector of ECL signals, and the detector employs a CCD-chip assembling matrix. Also provided are methods for high-throughput multi-analyte testing. The methods according to this disclosure are applied in various embodiments to test a broad range of analytes, including chemical compounds, proteins, peptides, DNAs, RNAs, antigens, antibodies, pathogens, contaminants, and derivatives thereof. | 04-11-2013 |
20140299468 | High-Performance Analytical Instrument and Method - Apparatus and methods are provided for improving sensitivity, throughput, and efficiency of multi-analyte analytical testing. Specifically, an improved Electrochemiluminescence (ECL) analytical apparatus is provided for analytical chemistry, diagnostics, and environmental applications. The ECL apparatus comprises a 96 or more-well plate, where a microarray of working electrodes is placed in each well for high throughput and multi-analyte testing. The microarray of working electrodes connects with a counter electrode forming a two-electrode electrochemical system. Each well is electrically addressable, thereby controlling ECL reactions in flexible modes. The ECL apparatus further comprises a detector of ECL signals, and the detector employs a CCD-chip assembling matrix. Also provided are methods for high-throughput multi-analyte testing. The methods according to this disclosure are applied in various embodiments to test a broad range of analytes, including chemical compounds, proteins, peptides, DNAs, RNAs, antigens, antibodies, pathogens, contaminants, and derivatives thereof. | 10-09-2014 |
Hongjun Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20090197349 | ELECTROCHEMILUMINESCENCE OF RARE EARTH METAL CHELATES - Luminescent chemical reagents that include complexes of rare earth metals with ligands such as aromatic heterocyclic nitrogen-containing compounds and semi-aromatic oxygen-containing compounds are used to detect small quantities of complex substances such as pharmaceuticals, metabolites, and microorganisms in complex sample mixtures. | 08-06-2009 |
Hong-Woon Yang, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20140234376 | Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease. | 08-21-2014 |
In Hong Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20100323434 | Compartmentalized Nerve Culture System - The present invention relates generally to a compartmentalized nerve culture system. The compartmentalized nerve culture system has numerous applications including isolation of axons and cell bodies. The present invention has broad application for basic and pre-clinical research including, but not limited to, use in neuroscience, neuronal culture systems, co-culture systems, drug screening, morphological studies, and toxicology studies. | 12-23-2010 |
James C. Yang, Silver Spring, MD US
Patent application number | Description | Published |
---|---|---|
20090042798 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provids an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 02-12-2009 |
20110104129 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 05-05-2011 |
20130195819 | T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials. | 08-01-2013 |
Jingping Yang, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090124516 | System for Providing Control Reactions for Real Time RT-PCR - Provided are methods and oligonucleotides useful as primers and templates for internal controls designed for use in Real Time Reverse Transcriptase Polymerase Chain Reactions. Use of the present methods and oligonucleotides allows validation of assay parameters and of the results that an assay set. | 05-14-2009 |
20100129325 | SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms. | 05-27-2010 |
20100190170 | MICROTITER PLATE MASK AND METHODS FOR ITS USE - Provided is a masking system of masks for use with multiwell plates such as microtiter plates to facilitate sample dispensing and assay accuracy, especially when dispensing more than one solution into the wells. One or more masks, adapted in size to fit snugly over a multiwell plate and the mask formed with openings each aligned with a subset of one or more wells of the plate beneath, aids the user in sample and/or reagent administration. Advantageously, the masks contain registration aids so that proper orientation with respect to the plate below is achieved; the registration aid may be a cut corner, registration peg or mark, or visual marking or stamping. | 07-29-2010 |
20120034676 | SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA | 02-09-2012 |
20140348798 | SENECA VALLEY VIRUS BASED COMPOSITIONS AND METHODS FOR TREATING DISEASE - The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms. | 11-27-2014 |
Jin-Ming Yang, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20090004462 | Inorganic-Organic Hybrid Nanocomposite Antiglare and Antireflection Coatings - Embodiments of this disclosure relate to compositions, and a method of making UV or heat curable anti-reflection and anti-glare hard coatings. Such coatings may be useful, for example, for simultaneously improving transmission and preventing undesired visible reflection on various monitor or display panels and optical lenses. For the panels with plastic covers, the coating will also improve the surface mechanical properties such as abrasion and scratch resistance. | 01-01-2009 |
Jyanyu Austin Yang, Columbia, MD US
Patent application number | Description | Published |
---|---|---|
20140294839 | Methylated Peptides Derived from Tau Protein and Their Antibodies for Diagnosis and Therapy of Alzheimer's Disease - In sporadic Alzheimer's disease, neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. Immunoassays have been developed recently that detect tau in biological specimens, thus providing a means for pre-mortem diagnosis of Alzheimer's disease, which has remained elusive. These assays have been improved by the analysis of relevant post-translational modifications, such as phosphorylation, however opportunity for improvement remains. The present invention addresses this issue by disclosing synthetic methylated peptides derived from the tau protein of paired helical filaments and non-diseased control brain. Alzheimer's disease specificity is provided by the presence or absence of methyl moieties on lysine residues and differences between mono-, di-, and tri-methylation. The methylated peptide is useful as an antigen and a binding partner for identifying compounds that interact with the peptide and the methylated tau protein, including antibodies that can distinguish non-diseased brain from that affected by Alzheimer's disease. The resulting antibodies are useful diagnostically and therapeutically. The compounds that specifically bind to methylated tau proteins are useful for eliminating abnormally methylated tau. | 10-02-2014 |
Mei Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20150231626 | Method and Apparatus for Microorganism Detection - A method for detecting the presence of a microorganism in a fluid sample is disclosed. The method includes providing a fluid specimen within a specimen collection container having a sidewall defining an interior therein. The interior includes a mechanical separator adapted for separating the fluid sample into first and second phases within the specimen collection container and a sensing element capable of detecting the presence of a microorganism disposed therein. The method includes subjecting the specimen collection container to applied rotational force to isolate a concentrated microorganism region. The method also includes detecting by a sensing element the presence or absence of a microorganism within the concentrated microorganism region. | 08-20-2015 |
Peixin Yang, Woodstock, MD US
Patent application number | Description | Published |
---|---|---|
20100291069 | METHODS OF TREATING A DIABETIC EMBRYOPATHY - Maternal diabetes can lead to a developmental malformation of an embryo. A developmental malformation caused by maternal diabetes is commonly referred to as a diabetic embryopathy. There is currently no effective treatment for reducing or inhibiting a diabetic embryopathy. To this end, the present invention is drawn to novel methods of treating a diabetic embryopathy. | 11-18-2010 |
20130316971 | USE OF TREHALOSE FOR PREVENTION OF NEURAL TUBE DEFECTS - Maternal diabetes suppresses autophagy in neuroepithelial cells of the developing neural tube which leads to neural tube defect formation. Trehalose treatment reversed autophagy impairment and prevented neural tube defects in diabetic pregnancies. Trehalose resolved homeostatic imbalance by correcting mitochondrial defects, dysfunctional proteins, ER stress, apoptosis, and delayed neurogenesis in the neural tubes exposed to hyperglycemia. Methods of using trehalose as an intervention against hyperglycemia-induced neural tube defects are provided herein. | 11-28-2013 |
Qiang Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20120027725 | SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES TO TREAT LIVER CANCER - The present application discloses a lentiviral transfer system for treating liver cancer which includes: (i) a self-inactivating transfer vector comprising: multiple gene units, wherein each gene unit includes a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and (ii) a helper construct which lacks a 5′ LTR, wherein the 5′ LTR has been replaced with a heterologous promoter, in which the helper construct further comprises: a lentiviral env nucleic acid sequence containing a deletion, wherein the deleted env nucleic acid sequence does not produce functional env protein; and a packaging signal contains a deletion, wherein the deleted packaging signal is nonfunctional. | 02-02-2012 |
Renji Yang, Silver Spring, MD US
Patent application number | Description | Published |
---|---|---|
20090263901 | STABLE NEURAL STEM CELL LINES - A systematic and efficient method for establishing stable neural stem cell lines and neuronal progenitor lines is described. The resulting cell lines provide robust, simple, and reproducible cultures of human and other mammalian neurons in commercially useful mass quantities while maintaining normal karyotypes and normal neuronal phenotypes. | 10-22-2009 |
Ronald Yang, Bel Air, MD US
Patent application number | Description | Published |
---|---|---|
20100153467 | ARRAY ATTRIBUTE CONFIGURATOR - An array attribute configurator configures a set of received values based upon a predetermined set of unique value fields of an array. Array attribute configurator determines if duplicates exist within the set of received values. Array attribute configurator determines if a unique value field lacks a corresponding value within the set of received values. Array attribute configurator configures an array attribute from the set of received values based upon these determinations. | 06-17-2010 |
Rongze Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20090317393 | METHOD OF MODIFYING GLUCOSE ACTIVITY USING POLYPEPTIDES SELECTIVELY EXPRESSED IN FAT TISSUE - Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition. | 12-24-2009 |
Rong-Ze Yang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20100021900 | USE OF OMENTIN 1 AND OMENTIN 2 IN THE DIAGNOSIS AND TREATMENT OF DISEASE - The present invention is directed to methods of diagnosing a disease or predicting an increased risk of a disease, such as obesity, obesity-dependent subacute inflammation, atherosclerosis, cardiovascular disease and a metabolic disease, by determining the levels of omentin 1 and 2 protein in a subject, or by determining the levels of omentin 1 and 2 gene expression in a subject. The present invention is also directed to methods of disease treatment using omentin 1 protein and omentin 2 protein. | 01-28-2010 |
Rong-Ze Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20080220417 | Novel Alanine Transaminase Enzymes and Methods of Use - Novel alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and/or tissue malfunction. The ALT polypeptides are murine and/or | 09-11-2008 |
20090280108 | SERUM AMYLOID A PROTEIN IN INFLAMMATION AND OBESITY - The present invention relates to the discovery that acute-phase serum amyloid protein A (A-SAA) is a biomarker for obesity and certain abnormal conditions. The present invention, therefore, provides methods of diagnosing obesity or an abnormal condition in a subject The present invention also provides methods of monitoring the progression of obesity or an abnormal condition in a subject. The present invention also relates to treating obesity or an abnormal condition comprising reducing the levels of active SAA1 and/or SAA2 in a subject in need thereof. | 11-12-2009 |
Samuel Yang, Columbia, MD US
Patent application number | Description | Published |
---|---|---|
20130217588 | Methods for Identifying Eubacteria - This invention relates, e.g., to methods for detecting a aubacterium, determining if the eubacterium is Gram-positive or Gram-negative, and determining the species of the eubacterium in a sample. | 08-22-2013 |
20150024953 | METHODS FOR IDENTIFYING EUBACTERIA - This invention relates, e.g., to methods for detecting a | 01-22-2015 |
Samuel Yang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20130096035 | SELF-SUSTAINED FLUIDIC DROPLET CASSETTE AND SYSTEM FOR BIOCHEMICAL ASSAYS - A fluidic cartridge for biochemical assays includes a cartridge body defining a first droplet region and a second droplet region with a droplet restraining barrier therebetween. The droplet restraining barrier has a gap between the first and the second droplet regions. The fluidic cartridge also includes a first droplet dispensed in the first droplet region. The first droplet includes a plurality of magnetic particles dispersed therein. The fluidic cartridge also includes a second droplet disposed in the second droplet region. The plurality of magnetic particles are sufficiently small to be drawn through the gap between the first and second droplet regions when compelled by an applied magnetic field, and the first droplet is restrained by the restraining barrier while the plurality of magnetic particles are drawn through the gap. A biochemical assay system includes a stage adapted to receive a fluidic cartridge, and a magnetic control assembly that includes a magnet. The magnet of the magnetic control assembly is movable to direct motion of magnetic particles contained within the fluidic cartridge. | 04-18-2013 |
Samuel Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20100203518 | Quantitative Assay for the Simultaneous Detection and Speciation of Bacterial Infections - An adaptation of the real-time PCR assay allows for highly sensitive detection of any eubacterial species with simultaneous speciation. The assay relies on a ‘multiprobe’ design in which a single set of highly conserved sequences encoded by the 16S rRNA gene serves as the primer pair, and it is used in combination with both an internal highly conserved sequence, the universal probe, and an internal variable region, the species-specific probe. A pre-PCR ultrafiltration step can be used to effectively decontaminate or remove background DNA. The real-time system reliably identifies 14 common bacterial species with a detection limit of 50 fg. | 08-12-2010 |
Sherry X. Yang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20120142624 | AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY - Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer. | 06-07-2012 |
20140011866 | AKT PHOSPHORYLATION AT SER473 AS AN INDICATOR FOR TAXANE-BASED CHEMOTHERAPY - Methods for determining whether a cancer patient is likely to benefit from treatment with a taxane compound based on Akt-Ser473 phosphorylation status are provided, together with kits for determining Akt-Ser473 phosphorylation status and methods for improving treatment of a cancer patient that include obtaining a determination of the Akt-Ser473 phosphorylation status of the cancer. | 01-09-2014 |
20140066393 | METHOD OF SELECTING CANCER PATIENTS FOR ANTI-ANGIOGENESIS THERAPY IN COMBINATION WITH CHEMOTHERAPY - What is described is a method for identifying a cancer patient that is amenable to anti-angiogenesis therapy in combination with chemotherapy for longer overall survival and/or progression-free survival by measuring the status of tumor cell HER2 expression, p53 expression, and apoptosis or endothelial cell CD31 expression in a tumor sample obtained from the patient prior to treatment. Bevacizumab, an antibody to vascular endothelial growth factor, is a preferred anti-angiogenesis therapy for treating several cancer types including breast cancer. Cancer patients with p53-negative or HER2 negative tumors, especially dual p53 HER2-negative tumors or tumors with low levels of apoptosis or high endothelial cell CD31 expression in the tumor samples are more amenable to anti-angiogenesis therapy with bevacizumab. These tumor characteristics provide a diagnostic method for identifying cancer patients amendable to anti-angiogenesis therapy plus chemotherapy for better treatment outcome. | 03-06-2014 |
Shuang Yang, Ellicott City, MD US
Patent application number | Description | Published |
---|---|---|
20140135235 | GLYCAN AND GLYCOPEPTIDE CAPTURE AND RELEASE USING REVERSIBLE HYDRAZONE-BASED METHOD - Highly specific and novel methods for reversible hydrazone solid-phase extraction (rHSPE) are provided for glycan or glycopeptide isolation from proteins, peptides, and other contaminants for glycan and glycopeptide analysis. Glycans or glycopeptides in complex mixtures can be conjugated onto solid support or affinity or chemical tags via reversible hydrazone bond. The conjugation methods of the present invention are chemically specific and provide unique means for the removal of other non-glycan containing molecules in the complex sample before the glycans or glycopeptides are hydrolyzed and recovered for analysis. The hydrazone formation and hydrolysis of the novel methods allows for the analysis of glycans and glycopeptides. The hydrazide coating on the solid-phase surfaces are useful for surface glycan capture and on target glycan analysis. Uses of the information generated by the inventive methods for diagnosis and treatment are also disclosed. | 05-15-2014 |
20150233903 | SOLID PHASE GLYCAN AND GLYCOPEPTIDE ANALYSIS AND MICROFLUIDIC CHIP FOR GLYCOMIC EXTRACTION, ANALYSIS AND METHODS FOR USING SAME - Highly specific and novel solid phase methods for analyzing glycans and proteoglycans using a solid phase system are provided. The present invention also provides an integrated apparatus and methods of use which comprises a high-throughput glycan isolation and reverse-phase liquid chromatography (RPLC) for on-chip glycan extraction, modification and separation. The coverage of detected N-glycans by the GIG-chip-LC apparatus of the present invention can be significantly improved, especially for the low abundant species. Chip-LC by PGC minimizes dynamic range of glycan concentrations in fractions, resulting in detection of low-abundance glycans. Glycan isomers were able to be separated by the chip-LC portion of the apparatus. The GIG-chip-LC apparatus of the present invention can be used to analyze glycans from tissue and sera samples, thus providing a reliable tool for glycomic analysis. The reproducible performance and ability to detect unique glycans from tissue samples provides a powerful means for discovery of abnormal glycans associated with disease states. | 08-20-2015 |
20150241437 | ISOBARIC ALDEHYDE-REACTIVE TAGS FOR AND ANALYSIS OF GLYCANS USING SAME - Highly specific and novel methods for analyzing glycans and proteoglycans are provided. Uses of the information generated by the inventive methods for diagnosis and treatment are also disclosed. | 08-27-2015 |
Shuwei Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20100167292 | HIGH FIDELITY POLYMERASES AND USES THEREOF - The present invention relates to a DNA and RNA polymerases which have increased fidelity (or reduced misincorporation rate). In particular, the invention relates to a method of making such polymerases by modifying or mutating the nucleotide binding domain of the polymerase (e.g., the O-helix). The invention also relates to DNA molecules containing the genes encoding the polymerases of the invention, to host cells containing such DNA molecules and to methods to make the polymerases using the host cells. The polymerases are particularly suited for nucleic acid synthesis, sequencing, amplification and cDNA synthesis. | 07-01-2010 |
Tyler T. Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20100005019 | HOME APPRECIATION PARTICIPATION NOTES - A method, computer program product and computer system for issuing and servicing a Home Appreciation Participation Note (HAPN) for a real estate property, which includes issuing an Participation Contract (PC) for the property to PC investors, where the PC has a value derived from a sharing formula based on a change of a proxy for the value of the property relative to an initial value of the proxy, and the proxy is independent of an actual current condition of the property (after the initial valuation); and issuing a HAPN Bond for the property to HAPN Bond investors, where the HAPN Bond has an initial value set as a sum of an amount paid for the PC and an amount paid for the HAPN Bond. Both the PC and the HAPN Bond represent claims on the property, and the HAPN Bond is a performance bond for the PC if the value of the PC is negative. | 01-07-2010 |
Xi Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20100068802 | NOVEL HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS AS BIOMARKERS AND THERAPEUTIC TARGETS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 03-18-2010 |
20120156770 | HUMAN ANDROGEN RECEPTOR ALTERNATIVE SPLICE VARIANTS - The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided. | 06-21-2012 |
Xiaochuan Yang, Towson, MD US
Patent application number | Description | Published |
---|---|---|
20150152056 | Curcumin Analogs and Methods of Making and Using Thereof - Compounds having Formula I or II, and methods of making and using thereof, are described herein: | 06-04-2015 |
Xiaochuan Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20150203442 | Anthraquinone Analogs and Methods of Making and Using Thereof - Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds. | 07-23-2015 |
Xiaohui Yang, Odenton, MD US
Patent application number | Description | Published |
---|---|---|
20080232738 | SYSTEMS AND METHODS FOR SIDE-LOBE COMPENSATION IN RECONFIGURABLE OPTICAL ADD-DROP MULTIPLEXERS - Systems and methods to reduce passband side-lobes associated with WSS-based ROADMs by applying a filter on each channel are provided. In an exemplary embodiment, a comb filter, such as a thin film filter or an interleaver, is utilized. Additionally, the present invention provides systems and methods to adaptively control amplifier target power and per wavelength target power to maintain signal launching power as per design in networks with WSS-based ROADMs. Accordingly, signal OSNR does not collapse faster than other similar configured system without WSS-based ROADM. In order to correct amplifier target power, the present invention utilizes system information about side-lobe size and OSNR at each amplifier. | 09-25-2008 |
20090097849 | PERFORMANCE OPTIMIZED RECEIVER WITH BANDWIDTH ADAPTIVE OPTICAL FILTER FOR HIGH SPEED LONG HAUL WDM SYSTEMS - The present invention provides a performance optimized receiver with a bandwidth adaptive optical filter for high speed long haul wavelength division multiplexed systems, such as 40 Gb/s and 100 Gb/s wavelength division multiplexed systems. The performance optimized receiver includes: a bandwidth and wavelength tunable optical filter, wherein the bandwidth and wavelength tunable optical filter is operable for receiving a plurality of wavelengths associated with a wavelength division multiplexed signal and passing one or more selected wavelengths, and wherein the bandwidth and wavelength tunable optical filter is operable for adjusting the bandwidth of each of the one or more selected wavelengths; and a receiver coupled to the bandwidth and wavelength tunable optical filter. Preferably, the receiver includes one or more of a bit error rate monitoring module and a signal quality monitoring module operable for monitoring the one or more selected wavelengths and providing feedback to the bandwidth and wavelength tunable optical filter such that the bandwidth and wavelength tunable optical filter adaptively adjusts the bandwidth of each of the one or more selected wavelengths. | 04-16-2009 |
20090116841 | Systems and methods for adaptive gain control to compensate OSNR penalty caused by side-lobe of MEMS-based reconfigurable optical add-drop multiplexers - The present invention provides systems and methods to adaptively control amplifier target power to maintain signal launching power as per design in networks with wavelength selective switch (WSS)-based reconfigurable optical add-drop multiplexers (ROADMs) using micro-electromechanical system (MEMS). Accordingly, signal OSNR does not collapse faster for WSS-based ROADMs than other similar configured system without WSS-based ROADM. In order to correct amplifier target power, the present invention utilizes system information about side-lobe size and OSNR at each amplifier. Related information, such as ASE level and size of side-lobes at each channel from upstream amplifiers, is passed to the network controller at each amplifier. Meanwhile, with target signal level and local WSS attenuation setting (given side-lobe size vs. WSS attenuation known) of each channel, the amplifier calculates what is total output power should be and adaptively maintains that power. | 05-07-2009 |
20100183311 | HIGH-DEGREE RECONFIGURABLE OPTICAL ADD-DROP MULTIPLEXING SYSTEMS USING BI-DIRECTIONAL WAVELENGTH SELECTIVE SWITCHES - The present disclosure provides high-degree reconfigurable optical add-drop multiplexing (ROADM) systems using bi-directional wavelength selective switches (WSSs) and optical circulators. A single WSS is utilized on each degree of a node in a bi-directional manner, i.e. both ingress and egress share the same WSS. Advantageously, the present invention eliminates conventional splitters/combiners thereby capping intra-node insertion loss to a certain value regardless of the number of degrees. More importantly, the present invention reduces noise penalty associated with high-degree nodes while minimizing cost. | 07-22-2010 |
Xiaoming Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20080208034 | Device, systems and methods for localized heating of a vessel and/or in combination with mr/nmr imaging of the vessel and surrounding tissue - Featured are devices, systems and methods for localized heating of a vessel as well as devices, systems and methods for MR/NMR imaging of a vessel while locally heating a portion of the vessel. More particularly featured are such devices, systems and methods for use when administering or delivering therapeutic agents including genes and/or drugs to the tissues of the vessel. Such a method includes positioning a thermal energy delivery device proximal a target site within the vessel of a body and activating the thermal energy delivery device so as to heat the target site thereby locally increasing a temperature of tissue at the target site. In further embodiments, the method includes introducing a therapeutic medium to the target site over a predetermined time period, and wherein said activating occurs at least one of before, during or after said step of introducing. | 08-28-2008 |
Yibin Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20160031957 | INHIBITORS OF THE LINEAR UBIQUITIN CHAIN ASSEMBLY COMPLEX (LUBAC) AND RELATED METHODS - The invention relates to peptide inhibitors of linear ubiquitin chain assembly complex (LUBAC) and to methods of treating diseases including activated B-cell like diffuse large B cell lymphboma (ABC DLBCL) and autoimmune or inflammatory disorders. | 02-04-2016 |
Yili Yang, Montgomery Village, MD US
Patent application number | Description | Published |
---|---|---|
20080306130 | Inhibitors of ubiquitin E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 12-11-2008 |
20100048593 | DEAZAFLAVIN COMPOUNDS AND METHODS OF USE THEREOF - The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention. | 02-25-2010 |
20100056549 | HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER - The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention. | 03-04-2010 |
20100305180 | INHIBITORS OF UBIQUITIN E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 12-02-2010 |
20120289569 | INHIBITORS OF UBIQUITIN E1 - The present invention features pyrazolidinyl compounds, pharmaceutical compositions of substituted pyrazolidinyl compounds and methods of treating a patient suffering from cancer or viral infection, the method comprising administering to a patient one or more pyrazolidinyl compounds of the invention. | 11-15-2012 |
Ying-Hua Yang, Timonium, MD US
Patent application number | Description | Published |
---|---|---|
20130004415 | Joint-Homing Peptides and Uses Thereof - The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein. | 01-03-2013 |
Yingzi Yang, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20140220154 | METHOD OF TREATING PATHOLOGIC HETEROTOPIC OSSIFICATION - What is described is a method of preventing or treating heterotopic ossification, vascular calcification, and pathologic mineralization, comprising administering an drug, wherein the drug is an antagonist of the Hedgehog (Hh) pathway. For example the antagonist consists of arsenic trioxide, sodium arsenite, phenylarsine, GANT-58, GANT-61, zerumbone vismodegib (GDC-0449, Genentech), bevacizumab, gemcitabine, nab-paclitaxel, FOLFIR, FOLFOX, RO4929097, cixutumumab, cisplatin, etoposide, LDAC, decitabine, daunorubicin, cytarabin, rosiglitazone, goserelin, leuprolide, capecitabine, fluorouracil, leucovorin, oxaliplatin, irinotecan, diclofenac, BMS-833923 (XL139), IPI-926—Infinity Pharmaceuticals, Inc., LDE225, LEQ506—Novartis Pharmaceuticals, TAK-441 Millennium Pharmaceuticals, Inc., and PF-04449913—Pfizer, alone or in combination therapy. The method targets pluripotent mesenchymal cells, wherein the antagonist inhibits expression of a gene encoding a Hh pathway component, for example by decreasing levels of mRNA encoded Ptch1, Gli1 or HIP. | 08-07-2014 |
Yixin Yang, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20120019148 | HIGH VOLTAGE POWER SUPPLY FOR POWERING A MAGNETRON IN A UV CURING LAMP ASSEMBLY - A power supply for use in a UV curing lamp assembly is disclosed. The power supply is powered by two intermediate frequency (200-400 Hz) low voltage sinusoidal power sources that drive the primary windings of a dual laminated transformer. The low voltage sinusoidal power sources are configured to have different phases. The out-of-phase low voltage sine wave sources are converted to high voltage sine waves on the secondary windings of the dual laminated transformer having the same phase difference relationship. A single rectifier comprising six high voltage diodes, called a ladder rectifier, combine the two out-of-phase sine waves into a single, approximately DC output power source. By modulating a phase difference between two input sine wave power sources, the approximate DC output voltage exiting the ladder rectifier may be alternated between a low ripple mode of about a 13.84% ripple, a high current mode, a high voltage mode, and an intermediate mode with a ripple in the range of about 13.84% to about 100%. | 01-26-2012 |
20140000840 | HEATING AND COOLING SYSTEM INCORPERATING A HEAT STORAGE TANK WITH HEAT PUMP PARTS | 01-02-2014 |
20140138550 | INTELLIGENT UV RADIATION SYSTEM - An “intelligent” UV curing assembly is disclosed. The “intelligent” assembly permits automated monitoring of performance parameters, part lifetime, and inventory control of internal parts. The “intelligent” assembly includes an on lamp microprocessor. The on lamp microprocessor may be configured to recognize the internal parts, record accumulated working time of each part, and sample and process data from the plurality of “intelligent” sensors. | 05-22-2014 |
Yongping Yang, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20140322163 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed. | 10-30-2014 |
20140348785 | NEUTRALIZING GP41 ANTIBODIES AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection. | 11-27-2014 |
20140348865 | IMMUNOGENS BASED ON AN HIV-1 V1V2 SITE-OF-VULNERABILITY - Disclosed are HIV immunogens. Also disclosed are nucleic acids encoding these immunogens and methods of producing these antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject. | 11-27-2014 |
Yongwen Yang, Columbia, MD US
Patent application number | Description | Published |
---|---|---|
20140082462 | METHOD AND APPARATUS FOR ENCODING AND DECODING HIGH SPEED SHARED CONTROL CHANNEL - A method and apparatus for encoding and decoding high speed shared control channel (HS-SCCH) data are disclosed. For part 1 data encoding, a mask may be generated using a wireless transmit/receive unit (WTRU) identity (ID) and a generator matrix with a maximum minimum Hamming distance. For part 2 data encoding, cyclic redundancy check (CRC) bits are generated based on part 1 data and part 2 data. The number of CRC bits is less than the WTRU ID. The CRC bits and/or the part 2 data are masked with a mask. The mask may be a WTRU ID or a punctured WTRU ID of length equal to the CRC bits. The mask may be generated using the WTRU ID and a generator matrix with a maximum minimum Hamming distance. The masking may be performed after encoding or rate matching. | 03-20-2014 |
Yongwen E. Yang, Columbia, MD US
Patent application number | Description | Published |
---|---|---|
20140376568 | METHOD AND APPARATUS FOR ENCODING CHANNEL QUALITY INDICATOR AND PRECODING CONTROL INFORMATION BITS - A method and apparatus for encoding channel quality indicator (CQI) and precoding control information (PCI) bits are disclosed. Each of the input bits, such as CQI bits and/or PCI bits, has a particular significance. The input bits are encoded with a linear block coding. The input bits are provided with an unequal error protection based on the significance of each input bit. The input bits may be duplicated based on the significance of each input bit and equal protection coding may be performed. A generator matrix for the encoding may be generated by elementary operation of conventional basis sequences to provide more protection to a most significant bit (MSB). | 12-25-2014 |
20150100863 | METHOD AND APPARATUS FOR ENCODING AND DECODING A HIGH SPEED SHARED CONTROL CHANNEL - A method and apparatus for encoding and decoding a data block are disclosed. The data block may be for a physical channel. Further, the data block may be for a shared channel. For data block encoding, a Node-B may calculate cyclic redundancy check (CRC) bits for the data block. The data block may be used to calculate the CRC bits. The Node-B may mask the CRC bits with a wireless transmit/receive unit (WTRU) identity (ID). Further, the Node-B may attached the masked CRC bits to the data block. Using a transmitter, the Node-B may transmit the data block over a physical channel. Further, the Node-B may transmit the data block over a shared channel. A WTRU may receive the data block, including the masked CRC bits. Using the WTRU ID, the WTRU may de-mask the CRC bits. The WTRU may perform a CRC check using the de-masked CRC bits. | 04-09-2015 |
20150139143 | METHOD AND APPARATUS FOR IMPLEMENTING SPACE TIME PROCESSING - A method and apparatus for implementing spatial processing with unequal modulation and coding schemes (MCSs) or stream-dependent MCSs are disclosed. Input data may be parsed into a plurality of data streams, and spatial processing is performed on the data streams to generate a plurality of spatial streams. An MCS for each data stream is selected independently. The spatial streams are transmitted via multiple transmit antennas. At least one of the techniques of space time block coding (STBC), space frequency block coding (SFBC), quasi-orthogonal Alamouti coding, time reversed space time block coding, linear spatial processing and cyclic delay diversity (CDD) may be performed on the data/spatial streams. An antennal mapping matrix may then be applied to the spatial streams. The spatial streams are transmitted via multiple transmit antennas. The MCS for each data stream may be determined based on a signal-to-noise ratio of each spatial stream associated with the data stream. | 05-21-2015 |
Youfeng Yang, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20080286770 | DNA Molecules Encoding L-Glutamate-Gated Chloride Channels From Rhipicephalus Sanguineus - The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode | 11-20-2008 |
Yu-Han Yang, College Park, MD US
Patent application number | Description | Published |
---|---|---|
20140185596 | SYSTEMS AND METHODS FOR TIME-REVERSAL DIVISION MULTIPLE ACCESS WIRELESS BROADBAND COMMUNICATIONS - There is provided a communication system including a transmitting section and a receiving section which includes a plurality of receivers. The transmitting section includes a communication unit which receives a plurality of signals respectively from the plurality of receivers, and stores a plurality of time-reversed signals corresponding to the received plurality of signals with respect to the plurality of receivers, and a first conversion unit which converts, by a first factor, a plurality of information sequences to be respectively transmitted to the plurality of receivers and forward the plurality of converted information sequences to the communication unit. The communication unit generates, based on the plurality of converted information sequences, a plurality of output signals to be respectively transmitted to the plurality of receivers, each of the plurality of the output signals including a location-specific signature unique to the corresponding receiver. | 07-03-2014 |
20150312081 | QUADRATURE AMPLITUDE MODULATION FOR TIME-REVERSAL SYSTEMS - Time-reversal wireless communication includes: at a base station, receiving a probe signal from a terminal device; generating a signature waveform that is based on a time-reversed signal of a channel response signal derived from the probe signal; performing quadrature amplitude modulation (QAM) on a transmit signal to generate a quadrature amplitude modulated signal; and generating a transmission signal based on the quadrature amplitude modulated signal and the signature waveform. | 10-29-2015 |
Zhiping Yang, Laurel, MD US
Patent application number | Description | Published |
---|---|---|
20150216731 | EAR WARMER FRAME - Apparatus described herein include ear warmer frames. In some embodiments, an apparatus includes a frame configured to be disposed about a portion of a head of a user. The frame includes a first member and a second member. The first member has a first portion and a second portion. The first portion of the first member has a cross-sectional profile, and the second portion of the first member has a cross-sectional profile smaller than the cross-sectional profile of the first portion of the first member. An end portion of the second member has a cross-sectional profile substantially corresponding to the cross-sectional profile of the first portion of the first member. The second member defines an opening configured to receive the second portion of the first member such that when the frame is in a collapsed configuration an abutment interface is defined, and surfaces of the abutment interface are substantially continuous between the first member and the second member. | 08-06-2015 |
Zhiyong Yang, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20110172206 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 07-14-2011 |
20130217679 | Compositions and Methods for Treatment of Neurodegenerative Disease - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 08-22-2013 |
20140187540 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 07-03-2014 |
20150258061 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASE - Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 09-17-2015 |
Zhi-Yong Yang, Potamac, MD US
Patent application number | Description | Published |
---|---|---|
20110177122 | DNA PRIME/ACTIVATED VACCINE BOOST IMMUNIZATION TO INFLUENZA VIRUS - The present invention relates to a combination of a priming composition and a boosting composition to prime and boost an immune response in a subject whereby the immune response resulting from administration of the priming composition to the subject is capable of being boosted. The priming composition comprises a DNA plasmid that comprises a nucleic acid molecule encoding an influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof. The boosting composition comprises an influenza vaccine. The present invention also relates to a method to use such a combination to vaccinate a subject and to enhance an immune response to an influenza vaccine administered alone. Such a combination can elicit an immune response not only against at least one influenza virus strain from which the priming composition or boosting composition is derived but also to at least one heterologous influenza virus strain. | 07-21-2011 |